MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

ImmunityBio Inc

Avatud

SektorTervishoid

2.61 -2.25

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.57

Max

2.72

Põhinäitajad

By Trading Economics

Sissetulek

27M

-59M

Müük

1.4M

7.6M

Aktsiakasum

-0.08

Kasumimarginaal

-783.62

Töötajad

680

EBITDA

946K

-40M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+126.02% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. mai 2025

Turustatistika

By TradingEconomics

Turukapital

-191M

2.2B

Eelmine avamishind

4.86

Eelmine sulgemishind

2.61

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

ImmunityBio Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

29. jaan 2025, 15:59 UTC

Suurimad hinnamuutused turgudel

ImmunityBio Shares Rise After Collaboration, Supply Agreement With BeiGene

24. okt 2024, 13:50 UTC

Omandamised, ülevõtmised, äriostud

This Biotech Stock Could Rocket 800%, Analyst Says -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

ImmunityBio Inc Prognoos

Hinnasiht

By TipRanks

126.02% tõus

12 kuu keskmine prognoos

Keskmine 6.08 USD  126.02%

Kõrge 8 USD

Madal 4.25 USD

Põhineb 3 Wall Streeti analüütiku instrumendi ImmunityBio Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

2

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

2.68 / 2.75Toetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest ImmunityBio Inc

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.